



Endologix
Investor Relations Department
2 Musick
Irvine, CA 92618
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ELGX

Last Trade:	4.26
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	0.00 (0.000%)
Day Range	4.16 - 4.31
52-Week Range	4.08 - 13.30
Volume	715,241

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S.

- **Addressing a signi... [\(more\)](#)**

Stock Performance



Press Releases [\[View all \]](#)

- Aug 17, 2017*
[Endologix Announces Positive Clinical Results from the LEOPARD Clinical Study](#)
- Aug 2, 2017*
[Endologix Reports Second Quarter 2017 Financial Results](#)
- Jul 12, 2017*
[Endologix, Inc. to Announce Second Quarter 2017 Financial Results on August 2, 2017](#)
- Jul 10, 2017*
[Endologix, Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference](#)
- Jun 3, 2017*
[Endologix Presents Positive Two-Year Clinical Data from the Nellix® EVAS FORWARD IDE Trial](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 4, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 8, 2016*
[Quarterly Report \(10-Q\)](#)